These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 19178127)

  • 1. Combination therapy as first-line treatment for hypertension.
    Crawford MH
    Am J Cardiovasc Drugs; 2009; 9(1):1-6. PubMed ID: 19178127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which is the optimal antihypertensive combination in different diseases, a renin- angiotensin-aldosterone system inhibitor with a diuretic or with a calcium channel blocker?
    Riva N; Lip GY
    Curr Pharm Des; 2013; 19(21):3753-65. PubMed ID: 23286431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing management of hypertension with combination therapy: considerations for the nurse practitioner.
    Roberts ME; Epstein BJ
    J Cardiovasc Nurs; 2009; 24(5):380-9. PubMed ID: 19707098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come?
    Weir MR; Bakris GL
    J Clin Hypertens (Greenwich); 2008 Feb; 10(2):146-52. PubMed ID: 18256579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
    Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newer renin-angiotensin-aldosterone system blocker combinations: is there an advantage?
    Lazich I; Bakris GL
    Curr Opin Nephrol Hypertens; 2011 Sep; 20(5):471-5. PubMed ID: 21709549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: extending the Guyton model.
    Hallow KM; Lo A; Beh J; Rodrigo M; Ermakov S; Friedman S; de Leon H; Sarkar A; Xiong Y; Sarangapani R; Schmidt H; Webb R; Kondic AG
    Am J Physiol Regul Integr Comp Physiol; 2014 May; 306(9):R647-62. PubMed ID: 24500431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials.
    Reboldi G; Gentile G; Angeli F; Verdecchia P
    Vasc Health Risk Manag; 2009; 5(1):411-27. PubMed ID: 19475778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
    Talbert RL
    J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents.
    Hanselin MR; Saseen JJ; Allen RR; Marrs JC; Nair KV
    Hypertension; 2011 Dec; 58(6):1008-13. PubMed ID: 22042809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal protection in hypertensive patients: selection of antihypertensive therapy.
    Wenzel RR
    Drugs; 2005; 65 Suppl 2():29-39. PubMed ID: 16398060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fixed-dose combination antihypertensives and reduction in target organ damage: are they all the same?
    Smith DH
    Am J Cardiovasc Drugs; 2007; 7(6):413-22. PubMed ID: 18076208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus.
    Reboldi G; Gentile G; Angeli F; Verdecchia P
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1349-61. PubMed ID: 19900018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with lercanidipine and enalapril in the management of the hypertensive patient: an update of the evidence.
    Antza C; Stabouli S; Kotsis V
    Vasc Health Risk Manag; 2016; 12():443-451. PubMed ID: 27895487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between cardiovascular outcomes and antihypertensive drug treatment in older women.
    Wassertheil-Smoller S; Psaty B; Greenland P; Oberman A; Kotchen T; Mouton C; Black H; Aragaki A; Trevisan M
    JAMA; 2004 Dec; 292(23):2849-59. PubMed ID: 15598916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using fixed-dose combination therapies to achieve blood pressure goals.
    Chrysant SG
    Clin Drug Investig; 2008; 28(11):713-34. PubMed ID: 18840014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of fixed-dose combination therapy with drugs that target the renin-angiotensin system in the hypertension paradigm.
    Schmieder RE
    Clin Exp Hypertens; 2010 Jan; 32(1):35-42. PubMed ID: 20144071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy for hypertension.
    Kaplan NM
    Nat Rev Cardiol; 2009 Apr; 6(4):270-1. PubMed ID: 19352329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of blood pressure in patients with diabetes.
    Grossman E; Messerli FH
    Am J Hypertens; 2011 Aug; 24(8):863-75. PubMed ID: 21525967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydrochlorothiazide versus calcium channel blockers: what is the best add-on to a renin-angiotensin system blocker for treating hypertension in patients with renal disease?
    Lerma EV
    Curr Hypertens Rep; 2011 Oct; 13(5):386-95. PubMed ID: 21796332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.